Gadolinium deposition in the brain: another concern regarding gadolinium-based contrast agents
- PMID: 26133320
- PMCID: PMC4498420
- DOI: 10.5152/dir.2015.001
Gadolinium deposition in the brain: another concern regarding gadolinium-based contrast agents
References
-
- Karabulut N, Elmas N. Contrast agents used in MR imaging of the liver. Diagn Interv Radiol. 2006;12:22–30. - PubMed
-
- Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104–1108. http://dx.doi.org/10.1093/ndt/gfk062. - DOI - PubMed
-
- Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–2362. http://dx.doi.org/10.1681/ASN.2006060601. - DOI - PubMed
-
- Aydingöz U. The need for radiologists’ awareness of nephrogenic systemic fibrosis. Diagn Interv Radiol. 2006;12:161–162. - PubMed
-
- Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010;31:440–446. http://dx.doi.org/10.1002/jmri.22024. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
